Literature DB >> 11386826

Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas.

S Y Yang1, G M Xu.   

Abstract

In this study, we detected the expression of platelet-derived growth factor (PDGF) and its receptor in 61 human meningiomas by immunohistochemistry and in situ hybridisation. The results showed that almost all the 61 meningiomas expressed PDGFBB and PDGF beta receptor and the positive rate of PDGFAA was 49%. Only two meningiomas expressed PDGF alpha receptor. The positive rate and the immunostaining intensity of PDGFBB and PDGF beta receptor were higher in atypical meningiomas than in benign types. There was no significant difference between the different types of benign meningiomas. The expression of PDGFB chain mRNA was coincident with that of PDGFB chain protein. There was no correlation between the expression of PDGFAA and the types or grades of meningiomas. The correlation between overexpression of PDGFBB/R beta and tumour grade provides a useful parameter in evaluating the prognosis of patients with meningiomas. The proliferative activity of meningiomas was evaluated by the proliferating cell nuclear antigen labelling index (PCNA LI). In the 61 meningiomas, the average PCNA LI (%) was 1.8+/-1.3, 1.9+/-1.3, 1.7+/-0.8 and 11.6+/-5.3 (in fibrous, meningothelial, transitional and atypical meningiomas, respectively). Statistic analysis shows that the PCNA LI is higher in atypical meningiomas than that in benign types, and there was no significant difference between the different types of benign meningiomas. The expression of PDGFBB and PDGF beta receptor was significant enhanced in ascending order from low PCNA LI meningiomas to high ones. This result suggested that PDGFBB/R beta autocrine loop may stimulate the growth of meningiomas. In this study, we also detected the cell apoptosis of meningiomas by terminal deoxynucleotidyl transferase mediated dUTP nick end labelling (TUNEL) method. The average apoptosis labelling index (%) was 0.11+/-0.05, 0.08+/-0.04, 0.09+/-0.03 and 0.35+/-0.15 in fibrous, meningothelial, transitional and atypical meningiomas respectively. The apoptosis labelling index was higher in atypical meningiomas than that in benign types. There was a positive correlation between the apoptosis labelling index and PC NA LI of meningioma. When the positive rate of PDGFBB and/or PDGF beta receptor was higher in meningioma, the apoptotic cells was also increased. In conclusion, the overexpression of PDGFBB and its relevant receptor PDGFR beta in meningiomas was correlated with grade of meningiomas and the proliferative activity of meningiomas; PDGFBB/R beta autocrine loop may play an critical role in the pathogenesis of meningiomas. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11386826     DOI: 10.1054/jocn.2001.0877

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  15 in total

1.  Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Authors:  David A Reardon; Andrew D Norden; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; John H Sampson; Sridharan Gururangan; Katherine B Peters; Roger E McLendon; Julie A Norfleet; Eric S Lipp; Jan Drappatz; Patrick Y Wen; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

2.  Adipose-derived stem cell-conditioned medium protects fibroblasts at different senescent degrees from UVB irradiation damages.

Authors:  Shu Guo; Ting Wang; Shuangyi Zhang; Peng Chen; Zheng Cao; Wenqin Lian; Jiayan Guo; Yue Kang
Journal:  Mol Cell Biochem       Date:  2019-10-10       Impact factor: 3.396

Review 3.  Emerging therapeutic targets in schwannomas and other merlin-deficient tumors.

Authors:  Sylwia Ammoun; C Oliver Hanemann
Journal:  Nat Rev Neurol       Date:  2011-06-07       Impact factor: 42.937

Review 4.  Molecular pathogenesis of meningiomas.

Authors:  Arie Perry; David H Gutmann; Guido Reifenberger
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

Review 5.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

6.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

7.  Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma.

Authors:  Hiromi Kanno; Hiroshi Nishihara; Lei Wang; Sayaka Yuzawa; Hiroyuki Kobayashi; Masumi Tsuda; Taichi Kimura; Mishie Tanino; Shunsuke Terasaka; Shinya Tanaka
Journal:  Neuro Oncol       Date:  2013-03-28       Impact factor: 12.300

Review 8.  Medical management of meningiomas.

Authors:  Wendy J Sherman; Jeff J Raizer
Journal:  CNS Oncol       Date:  2013-03

9.  Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Authors:  Thomas J Kaley; Patrick Wen; David Schiff; Keith Ligon; Sam Haidar; Sasan Karimi; Andrew B Lassman; Craig P Nolan; Lisa M DeAngelis; Igor Gavrilovic; Andrew Norden; Jan Drappatz; Eudocia Quant Lee; Benjamin Purow; Scott R Plotkin; Tracy Batchelor; Lauren E Abrey; Antonio Omuro
Journal:  Neuro Oncol       Date:  2014-08-06       Impact factor: 12.300

Review 10.  Glioblastoma simultaneously present with adjacent meningioma: case report and review of the literature.

Authors:  Kengo Suzuki; Hiroyuki Momota; Akiko Tonooka; Hiroko Noguchi; Kouhei Yamamoto; Masahiko Wanibuchi; Yoshihiro Minamida; Tadashi Hasegawa; Kiyohiro Houkin
Journal:  J Neurooncol       Date:  2010-01-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.